1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EB047EE87FFAE0390025870C006EFF0D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-leveraging-outcomes-data-launch-investment-technology-health-economics-outcomes-research-oncology-products?opendocument
18
19opendocument
203.231.230.177
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Leveraging Outcomes Data – Launch Investment and Technology in Health Economics & Outcomes Research in Oncology Products

ID: 5687


Features:

11 Info Graphics

8 Data Graphics

100+ Metrics

2 Narratives


Pages/Slides: 27


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Leveraging Outcomes Data: Launch Investment and Technology in Health Economics & Outcomes Research in Oncology Products"


STUDY OVERVIEW


Demonstrating an oncology drug’s value proposition and its potential in real-world practice will maximize business and clinical success. The Health Economics Outcomes Research function is a key player in generating value-oriented outcomes data, but it needs to effectively communicate outcomes data to external and internal stakeholders. Likewise, organizations need to invest in HEOR activities before and during clinical development to maximize launch success.

This study shows when organizations with oncology products are investing in HEOR activities during development to best support launch and what technology/tools best communicate outcomes information to internal and external stakeholders.

Segmentation based on two areas: Geographic responsibility and HEOR reporting structure


KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Launch Investment for HEOR Activities
  • Technology and Tools
KEY METRICS

I. Launch Investment for HEOR Activities

  • Point at which investment is started and point at which maximum investment is reached in the listed HEOR activities to develop value assessments for new therapies
  • Point at which investment is started and point at which maximum investment is reached in the listed HEOR activities to develop value assessments for new therapies - Market Access
  • Point at which investment is started and point at which maximum investment is reached in the listed HEOR activities to develop value assessments for new therapies - Medical Affairs
  • Launch investment timeline in HEOR activities - Large companies
  • Launch investment timeline in HEOR activities - small/mid-sized companies

II. Technology and Tools
  • Effective technologies for field communication
  • Highly effective technologies for field communication – Global vs. U.S.; Market Access vs. Medical Affairs
  • Frequency of technology update
  • Frequency of updating effective technologies to enable field communication tools
  • Tools used by HEOR group to showcase value/ communicate with payers

SAMPLE KEY FINDINGS

  • Technology: Utilize value dossiers to directly support the positioning of new drugs and communicate drug value.
METHODOLOGY

Conducted an operational HEOR benchmark analysis engaging 27 HEOR leaders working across 19 top life-science companies. Report segments included geographic responsibility and functional reporting structure.


Industries Profiled:
Pharmaceutical; Consumer Products; Biotech; Health Care; Laboratories; Diagnostic; Communications; Biopharmaceutical


Companies Profiled:
AbbVie; Merck Serono; Novartis; Astellas; Boehringer Ingelheim; Pfizer; Eisai; Takeda Pharmaceuticals; Ipsen; Merck Sharp & Dohme; Daiichi Sankyo; Alkem; Foundation Medicine; Sun Pharmaceutical; Karyopharm Therapeutics; Brii Biosciences; Nucleus Global; Seattle Genetics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.